LWLu Wen

Lu Wen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lu Wen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Jumei Zhou

    Department of Radiation Oncology and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital, Central South University, Changsha, China

    2 shared publications
  • Xiaoping Yu

    Department of Diagnostic Radiology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China

    2 shared publications
  • En-Hao Yu

    Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiang Ya School of Medicine, Central South University, Changsha, People’s Republic of China

    1 shared publication
  • Fang Cao

    Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya, Central South University

    1 shared publication
  • Fang Cao

    Department of Pathology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China

    1 shared publication
  • Feng Bi

    Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

    1 shared publication

Latest Publications

  • Value of Post-NAC CT-based Node-RADS score for Predicting residual lymph node metastasis and survival outcome of locally advanced gastric cancer

    by Yan Sun, Hua Xiao, Lu Wen, Wang Xiang, Xiangtong Luo, Xiaohuang Yang, Lian Chen, Yanhui Yang, Yi Zhang, Sanqiang Yu, et al.

    Objectives The Node Reporting and Data System (Node-RADS) provides structured and effective evaluation for lymph nodes in malignancies. This study aims to investigate its value in predicting residual lymph node metastasis (LNM) and survival outcome of locally advanced gastric cancer (LAGC). Materials and methods This retrospective study included 118 patients with LAGC underwent neoadjuvant chemotherapy (NAC) and gastrectomy from April 2015 to June 2020. The diagnostic performance of the post-NAC CT-based Node-RADS score for regional LNM, both at the patient level and at the perigastric/extragastric subgroup level, was estimated using area under receiver operating characteristic curve (AUC) and Youden’s index. Kaplan-Meier curve was employed for prognostic analyses between high/low Node-RADS score group. A predictive Node-RADS (NR) model for LNM was developed using logistic regression analyses and a prognostic NR model for overall survival (OS) was developed using Cox regression analyses. Results In the prediction of LNM, the Node-RADS score exhibited an AUC of 0.843 (95%CI: 0.765–0.921) at patient level, 0.838 (95%CI: 0.757–0.918) in perigastric subgroup and 0.813 (95%CI: 0.724–0.901) in extragastric subgroup, surpassing LN short-axis criteria (AUC:0.664 [95%CI: 0.584–0.743], p < 0.001). The AUC of the NR predictive model for LNM increased to 0.870 (95%CI: 0.795–0.945), with 88.7% sensitivity and 78.9% specificity. The Node-RADS score was significantly correlated with post-NAC pathological status, and served as an independent indicator for OS (all p < 0.05).The NR prognostic model exhibited a Harrell's consistency index (C-index) of 0.724 (95%CI: 0.663–0.785), with no significant difference from the pathological prognostic model (0.739 [95%CI: 0.677–0.801], p = 0.695). Conclusion The post-NAC Node-RADS score provides accurate prediction of regional LNM and shows promising prognostic value for LAGC patients. Post-NAC Node-RADS related predictive models show potential in early identification of high-risk LAGC patients with residual lymph nodes or poor prognosis after NAC.


  • Open Access

    MRI-based radiomic nomogram for predicting disease-free survival in patients with locally advanced rectal cancer

    by Jun Liu, Ke Liu, Fang Cao, Pingsheng Hu, Feng Bi, Siye Liu, Lian Jian, Jumei Zhou, Shaolin Nie, Qiang Lu, et al.

    Purpose Individual prognosis assessment is of paramount importance for treatment decision-making and active surveillance in cancer patients. We aimed to propose a radiomic model based on pre- and post-therapy MRI features for predicting disease-free survival (DFS) in locally advanced rectal cancer (LARC) following neoadjuvant chemoradiotherapy (nCRT) and subsequent surgical resection. Methods This retrospective study included a total of 126 LARC patients, which were randomly assigned to a training set (n = 84) and a validation set (n = 42). All patients underwent pre- and post-nCRT MRI scans. Radiomic features were extracted from higher resolution T2-weighted images. Pearson correlation analysis and ANOVA or Relief were utilized for identifying radiomic features associated with DFS. Pre-treatment, post-treatment, and delta radscores were constructed by machine learning algorithms. An individualized nomogram was developed based on significant radscores and clinical variables using multivariate Cox regression analysis. Predictive performance was evaluated by the C-index, calibration curve, and decision curve analysis. Results The results demonstrated that in the validation set, the clinical model including pre-surgery carcinoembryonic antigen (CEA), chemotherapy after radiotherapy, and pathological stage yielded a C-index of 0.755 (95% confidence interval [CI]: 0.739–0.771). While the optimal pre-, post-, and delta-radscores achieved C-indices of 0.724 (95%CI: 0.701–0.747), 0.701 (95%CI: 0.671–0.731), and 0.625 (95%CI: 0.589–0.661), respectively. The nomogram integrating pre-surgery CEA, pathological stage, alongside pre- and post-nCRT radscore, obtained the highest C-index of 0.833 (95%CI: 0.815–0.851). The calibration curve and decision curves exhibited good calibration and clinical usefulness of the nomogram. Furthermore, the nomogram categorized patients into high- and low-risk groups exhibiting distinct DFS (both P < 0.0001). Conclusions The nomogram incorporating pre- and post-therapy radscores and clinical factors could predict DFS in patients with LARC, which helps clinicians in optimizing decision-making and surveillance in real-world settings.


  • Open Access

    Measurement of the distance between tumor micro-foci and gross tumor in rectal cancer pathological specimens: implication on margin distance of clinical target volume treated with high-dose radiotherapy for rectal cancer

    by Xu-Jie Bao, Xiao-Yan Chen, Lu Wen, Yuan-Yuan Liu, En-Hao Yu, Zheng Wu, Ke Liu, Ju-Mei Zhou, Su-Yu Zhu

    Purpose: To measure the micro-foci distance away from gross tumor and to provide reference to create the clinical target volume (CTV) margin for boost radiotherapy in rectal adenocarcinoma. Methods: Twenty-eight rectal cancer surgical specimens of only total mesorectal excision were collected. The pathological specimens were retrospectively measured, and the nearest distance between the tumor micro-foci and gross tumor was microscopically measured. The “in vivo–in vitro” retraction factor was calculated as the ratio of the deepest thickness laterally and the vertical height superior/inferiorly of the rectal tumor measured in MRI and those measured in immediate pathological specimens. The retraction factor during pathological specimen processing was calculated as the distance ratio before and after dehydration in the lateral, superior, and inferior sides by the “knot marking method.” The distances of tumor micro-foci were individually corrected with these two retraction factors. Results: The mean “in vivo–in vitro” tumor retraction factors were 0.913 peripherally and 0.920 superior/inferiorly. The mean tumor specimen processing retraction factors were 0.804 peripherally, 0.815 inferiorly, and 0.789 superiorly. Of 28 patients, 14 cases (50.0%) had 24 lateral micro-foci, 8 cases (28.6%) had 13 inferior micro-foci, and 7 cases (25.0%) had 19 superior micro-foci. The 95th percentiles of the micro-foci distance for 28 patients were 6.44 mm (peripheral), 5.54 mm (inferior), and 5.42 mm (superior) after retraction correction. Conclusion: The micro-foci distances of 95% of rectal adenocarcinoma patients examined were within 6.44 mm peripherally, 5.54 mm inferiorly, and 5.42 mm superiorly. These findings provide reference to set the boost radiotherapy CTV margin for rectal cancer.

  • Open Access

    MRI-based radiomic nomogram for predicting disease-free survival in patients with locally advanced rectal cancer

    by Lu Wen, Jun Liu, Pingsheng Hu, Feng Bi, Siye Liu, Lian Jian, Jumei Zhou, Shaolin Nie, Fang Cao, Qiang Lu, et al.

    Individual prognosis assessment is of paramount importance for treatment decision-making and active surveillance in cancer patients. We aimed to propose a radiomic model based on pre- and post-therapy MRI features for predicting disease-free survival (DFS) in locally advanced rectal cancer (LARC) following neoadjuvant chemoradiotherapy (nCRT) and subsequent surgical resection. This retrospective study included a total of 126 LARC patients, which were randomly assigned to a training set (n=84) and a validation set (n=42). All patients underwent pre- and post-nCRT MRI scans. Radiomic features were extracted from higher resolution T2 -weighted images. Pearson correlation analysis and ANOVA or Relief were utilized for identifying radiomic features associated with DFS. Pre-treatment, post-treatment, and delta radscores were constructed by machine learning algorithms. An individualized nomogram was developed based on significant radscores and clinical variables using multivariate Cox regression analysis. Predictive performance was evaluated by the C-index, calibration curve, and decision curve analysis. The results demonstrated that in the validation set, the clinical model including pre-surgery Carcinoembryonic Antigen (CEA), chemotherapy after radiotherapy, and pathological stage yielded a C-index of 0.755 (95% confidence interval [CI]: 0.630-0.880). While the optimal pre-, post-, and delta-radscores achieved C-indices of 0.724 (95%CI: 0.585-0.863), 0.701 (95%CI: 0.544-0.858), and 0.625 (95%CI: 0.439-0.811), respectively. The nomogram integrating pre-surgery CEA, pathological stage, alongside pre- and post-nCRT radscore, obtained the highest C-index of 0.833 (95%CI: 0.694-0.972). The calibration curve and decision curves exhibited good calibration and clinical usefulness of the nomogram. Furthermore, the nomogram categorized patients into high- and low-risk groups exhibiting distinct DFS (both P<0.0001). In summary, the nomogram incorporating pre- and post-therapy radscores and clinical factors could predict DFS in patients with LARC, which warrants further external validations.